{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vestibular-neuronitis/management/management/","result":{"pageContext":{"chapter":{"id":"f6abc1bb-cef0-5ec3-abe6-ca99c3f79fa7","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 134d7600-85b6-4660-800a-c31a29111b77 --><h2>Scenario: Management</h2><!-- end field 134d7600-85b6-4660-800a-c31a29111b77 -->","summary":"Covers the management of vestibular neuronitis, including symptomatic drug treatment, advice to patients, and referral.","htmlStringContent":"<!-- begin item 2cbd270d-4ae4-4181-a96a-96f897d8fe46 --><!-- begin field fa896a45-61af-4a88-a344-acbc01587cc5 --><p>From age 18 years onwards.</p><!-- end field fa896a45-61af-4a88-a344-acbc01587cc5 --><!-- end item 2cbd270d-4ae4-4181-a96a-96f897d8fe46 -->","topic":{"id":"4161326f-3a9d-549b-a377-dc2f2a6f809a","topicId":"d53e1081-ae57-4dcc-8ee8-14e6be6fb3d6","topicName":"Vestibular neuronitis","slug":"vestibular-neuronitis","lastRevised":"Last revised in November 2017","chapters":[{"id":"1371e2f5-4cd3-5674-aae3-79470e21b62b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cb3f7155-69a7-5a7f-b8c1-2a1a113f0070","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a45dcd81-fea0-598a-ba01-782b350ffabd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06a83e39-ba88-5cb5-872a-7b5e56e06a3c","slug":"changes","fullItemName":"Changes"},{"id":"c9683178-6f5b-5445-a2d4-02d27c379f4b","slug":"update","fullItemName":"Update"}]},{"id":"a9baddc3-bb87-54e7-b6bf-fb890ce8d86d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"65c0b807-ad55-5cb6-8ac0-1beaf353fd29","slug":"goals","fullItemName":"Goals"},{"id":"c577b7a6-4f03-5974-a443-32000f43d67c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"300cd325-7e03-5d62-afb6-803945166705","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e3892d6-0403-52e9-a509-fc65bd12340b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c67ef3c1-dad6-5fbc-9fc2-1f9ef2f8fcef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e83fe4f4-878e-59eb-a20b-f35218ed5023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4fd633a-c05b-5b41-9dc2-d862bc4286b5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8ab4ebcd-03e4-5892-9e29-aabb20cb8f45","slug":"definition","fullItemName":"Definition"},{"id":"552f3d90-3666-593b-b806-28115dcd8f3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1966c14e-e128-5b21-bbce-6b9d4f48924d","slug":"complications","fullItemName":"Complications"},{"id":"f30ad763-2643-586e-9d19-cffd5f45d021","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"adbff71b-d255-5959-953d-3b2788094c8b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"081f5ce9-172b-5beb-9ace-bbe7a9e86705","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ba7e323e-e894-5821-9164-ea7cd07a38b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7c05a5c3-6c86-5daa-aed5-df8280f3723a","fullItemName":"Management","slug":"management","subChapters":[{"id":"f6abc1bb-cef0-5ec3-abe6-ca99c3f79fa7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"1ae90a52-6113-534c-8cf7-46d78bb039a3","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"354fa7f8-799b-53ab-900a-b4083df52ec8","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"4df87a4b-4d5c-56b0-b766-c143a60b38e8","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"ac9da5a7-a091-516f-a6b1-03ed2d2f7156","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"9f00019c-78be-54da-b9cb-69c6c04c5063","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c39d54c3-45ec-52b9-9dd2-efc3f3caa200","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d04e0140-1610-5826-9319-63f03c35c2d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"763af5f7-891e-5c76-9970-ae093e35ae7b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d0088dd9-7199-53a5-a4d0-e4299a54c061","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c9ae115f-4e3a-5af0-870e-16c967836515","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"27450791-3a41-5a8d-951b-efe744ca7944","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49115179-8551-5f4b-9d71-06a60c3445da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7c05a5c3-6c86-5daa-aed5-df8280f3723a","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"7a8595f1-b950-5045-9f14-5e19bdfd0559","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field 4bf55992-7a0d-4aae-8a90-7222469f7710 --><h3>What should I advise a person with vestibular neuronitis?</h3><!-- end field 4bf55992-7a0d-4aae-8a90-7222469f7710 -->","summary":null,"htmlStringContent":"<!-- begin item 30a2e0ec-50de-4f6e-a9e3-b802abfa071e --><!-- begin field a9c64581-9868-4c19-be82-0db980a004b2 --><ul><li><strong>Reassure the person that symptoms will usually settle over several weeks, </strong>even if no treatment is given. Advise that factors such as alcohol, tiredness, or intercurrent illness may have a greater than usual effect on their balance. Explain that there may be periods during their recovery when their symptoms appear to be worsening again.</li><li><strong>Advise that bed rest may be necessary </strong>if symptoms are particularly severe during the acute phase, but that activity should be resumed as soon as possible (even if vertigo becomes more prominent during movement).</li><li><strong>Advise on safety issues.</strong><ul><li><strong>Advise the person not to drive when they are dizzy, or if they are likely to experience an episode of vertigo while driving.</strong><ul><li>The Driver and Vehicle Licensing Agency (DVLA) states that people with 'liability to sudden and unprovoked or unprecipitated episodes of disabling dizziness' should stop driving and inform the DVLA. For more information, see the DVLA publication <a data-hyperlink-id=\"20ce640c-022c-4881-a5bf-a98c00f9741c\" href=\"https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals\">Assessing fitness to drive: a guide for medical professionals.</a></li></ul></li><li><strong>Workplace </strong>— the person should inform their employer if their vertigo poses a risk in the workplace (for example people using ladders, operating heavy machinery, or driving).</li><li><strong>Falls in the home </strong>— discuss the risk of falling in the home during an episode of vertigo and suggest measures to reduce this.</li></ul></li><li><strong>Offer the person written information,</strong> such as that provided by NHS on <a data-hyperlink-id=\"59e32eef-9806-4a04-a1e6-a98c00f9742a\" href=\"https://www.nhs.uk/conditions/vestibular-neuronitis/\">Vestibular neuronitis</a>.</li></ul><!-- end field a9c64581-9868-4c19-be82-0db980a004b2 --><!-- end item 30a2e0ec-50de-4f6e-a9e3-b802abfa071e -->","subChapters":[{"id":"f11972c8-bcff-53e4-9d40-17a03392b1cc","slug":"basis-for-recommendation-e39","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ab258cbd-9e06-4340-b1ec-071570ff7f72 --><h4>Basis for recommendation</h4><!-- end field ab258cbd-9e06-4340-b1ec-071570ff7f72 -->","summary":null,"htmlStringContent":"<!-- begin item e3935b0a-dde9-46bb-a584-5218c7c934c3 --><!-- begin field 45f3f4cc-5e99-4fe8-aa73-bde2775e67c7 --><h5>Reassurance</h5><ul><li>The recommendation to reassure people that symptoms will settle is based on expert opinion in review articles that central vestibular compensation will improve symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Macleod and McAuley, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Bronstein and Lempert, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Wipperman, 2014</a>]. The advice on the fluctuant nature of the recovery process and factors which may affect balance more than usual is based on expert opinion from previous reviewers of this CKS topic. </li></ul><h5>Rest and activity</h5><ul><li>The recommendation to rest if necessary during the acute phase, but to encourage activity, is extrapolated from expert opinion in review articles. Some experts recommend bed rest for a maximum of 3 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Kaski and Bronstein, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Dommaraju and Perera, 2016</a>] and it is thought that vestibular compensation can develop more quickly and more effectively if the person is active as soon as possible [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Greco et al, 2014</a>].  </li></ul><h5>Safety advice</h5><ul><li>The recommendation on driving is based on information in the Driver and Vehicle Licensing Agency (DVLA) publication <em>Assessing fitness to drive: a guide for medical professionals </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">DVLA, 2017</a>].</li><li>The recommendation to advise on workplace safety and the risk of falls is pragmatic, based on what CKS considers to be good clinical practice, and has been extrapolated from expert opinion in a US guideline on the management of benign paroxysmal positional vertigo (BPPV) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Bhattacharyya et al, 2017</a>] and the occupational risks of BPPV outlined in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Parnes et al, 2003</a>].  </li></ul><h5>Offering written information</h5><ul><li>This recommendation is pragmatic, and is based on what CKS considers to be good clinical practice.</li></ul><!-- end field 45f3f4cc-5e99-4fe8-aa73-bde2775e67c7 --><!-- end item e3935b0a-dde9-46bb-a584-5218c7c934c3 -->","subChapters":[]}]},{"id":"867561df-8922-5158-b171-9af7ca00756b","slug":"symptomatic-drug-treatment","fullItemName":"Symptomatic drug treatment","depth":3,"htmlHeader":"<!-- begin field bc5875af-5665-4f33-9a17-ff5e96ccd09b --><h3>How should I treat the symptom of vertigo?</h3><!-- end field bc5875af-5665-4f33-9a17-ff5e96ccd09b -->","summary":null,"htmlStringContent":"<!-- begin item 8d612dac-2af4-4c62-87bf-0256216e9e37 --><!-- begin field 588168fc-5511-432c-9657-ef087b76b5da --><ul><li><strong>If symptoms are severe, offer short-term symptomatic drug treatment.</strong></li><li><strong>To <em>rapidly </em>relieve severe nausea or vomiting associated with vertigo, </strong>consider giving buccal prochlorperazine, or an intramuscular injection of prochlorperazine or cyclizine. </li><li><strong>To alleviate less severe nausea, vomiting, and vertigo, </strong>consider prescribing a short oral course of prochlorperazine, or an antihistamine (cinnarizine, cyclizine, or promethazine teoclate). <ul><li>Advise the person to take medication regularly for up to 3 days. Explain that medication should be taken for the minimum time possible, as it may delay recovery by affecting the body's compensatory mechanisms.</li><li>For more information, see <a class=\"topic-reference internal-reference\" href=\"/topics/vestibular-neuronitis/prescribing-information/\">Prescribing information</a>.</li></ul></li><li>Treatment with antiviral drugs, corticosteroids, or benzodiazepines is not recommended.</li><li>Advise the person to return if their symptoms deteriorate or have not fully resolved after 1 week.</li></ul><!-- end field 588168fc-5511-432c-9657-ef087b76b5da --><!-- end item 8d612dac-2af4-4c62-87bf-0256216e9e37 -->","subChapters":[{"id":"142cd65d-b2d6-5aa9-bf54-5909ba4cbd4e","slug":"basis-for-recommendation-47d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a9328d02-3ba3-43d9-adc8-cf0f2ef17ea5 --><h4>Basis for recommendation</h4><!-- end field a9328d02-3ba3-43d9-adc8-cf0f2ef17ea5 -->","summary":null,"htmlStringContent":"<!-- begin item 47d57110-4b67-4878-8909-a2b640319569 --><!-- begin field 517a06b0-beb0-4445-90aa-afd84e1b2ff6 --><h5>Offering symptomatic drug treatment</h5><ul><li>The recommendation that symptomatic treatment can be useful in the short term in the acute phase of vestibular neuronitis is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Greco et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Vestibular Disorders Association, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">van Vugt et al, 2017</a>]. </li></ul><h5>Choice of drug treatment</h5><ul><li>CKS found no good quality evidence of benefit for the different symptomatic treatment options. However, vestibular suppressant medications (for example antihistamines and antiemetics) are recommended by expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Greco et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Ludman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Wipperman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">van Vugt et al, 2017</a>] and the suggested drugs are all licensed for use in people with nausea, vomiting, and vertigo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">ABPI Medicines Compendium, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">MHRA, 2017</a>].  </li><li>The route of administration should be based on clinical judgement and the licensed indications of the specific drug. Experts suggest considering the intramuscular route for people in the acute phase who are experiencing severe nausea and reduced gastric motility [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Greco et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Ludman, 2014</a>].  </li></ul><h5>Duration of drug treatment</h5><ul><li>Expert opinion in review articles widely suggests that symptomatic drug treatment should only be used in the short term until vertigo begins to recede (2–3 days), because prolonged use may delay central vestibular compensation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Bronstein and Lempert, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Jeong et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Greco et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Royal and Vargas, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Vestibular Disorders Association, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Wipperman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Strupp et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Dommaraju and Perera, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">van Vugt et al, 2017</a>].  </li></ul><h5>Corticosteroids, antiviral drugs, and benzodiazepines</h5><ul><li>Some experts consider that corticosteroids may be useful in people with vestibular neuronitis, however evidence is insufficient to support their routine use<strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Goddard and Fayad, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Wipperman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Strupp et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">van Vugt et al, 2017</a>].   <ul><li>Evidence from a systematic review and meta-analysis suggests that, compared with placebo, corticosteroids for vestibular neuronitis cause improvement on caloric testing, but do not affect clinical symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Goudakos et al, 2010</a>].</li><li>A subsequent Cochrane systematic review (search date December 2010) had similar findings; when corticosteroids and placebo were compared, there was no significant difference in terms of vertigo at 24 hours and using the Dizziness Handicap inventory care at one, three, six, and twelve months. The Cochrane authors concluded that evidence is insufficient for both short- and long-term corticosteroid treatment for vestibular neuronitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Fishman et al, 2011</a>].  </li></ul></li><li>Antiviral medication has also been considered as an option for treating vestibular neuronitis, but evidence to support its effectiveness is lacking [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Goddard and Fayad, 2011</a>].<ul><li>Evidence from a prospective study with some methodological limitations found that methylprednisolone improved the vestibular recovery of people with vestibular neuronitis, but valaciclovir did not [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Strupp et al, 2004</a>].</li></ul></li><li>Benzodiazepines are not recommended because although some experts advocate their use, CKS found no evidence to support this, and they are not licensed for treating nausea, vomiting, or vertigo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>], and have the potential for dependence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Dommaraju and Perera, 2016</a>].  </li></ul><h5>Advice to return if symptoms deteriorate or do not resolve after 1 week </h5><ul><li>This recommendation is based on expert opinion from previous reviewers of this CKS topic who suggest that it is appropriate to refer after 1 week to exclude more serious diagnoses if symptoms persist despite treatment. It is also supported by the fact that the severe, acute symptoms of vestibular neuronitis usually resolve within a few days (although a milder feeling of unsteadiness and imbalance can last for weeks) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Goddard and Fayad, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Jeong et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Wipperman, 2014</a>].</li></ul><!-- end field 517a06b0-beb0-4445-90aa-afd84e1b2ff6 --><!-- end item 47d57110-4b67-4878-8909-a2b640319569 -->","subChapters":[]}]},{"id":"88f24da6-7eb4-5ff2-88c4-c367f557210c","slug":"admission-or-referral","fullItemName":"Admission or referral","depth":3,"htmlHeader":"<!-- begin field 190c547d-3ae4-4d7d-9c4a-45c1776df3db --><h3>When should I admit or refer a person with vestibular neuronitis?</h3><!-- end field 190c547d-3ae4-4d7d-9c4a-45c1776df3db -->","summary":null,"htmlStringContent":"<!-- begin item 1725e4d4-f04e-40b7-b9d0-ff0a56d38c24 --><!-- begin field ca375e99-945b-426a-8fe6-8087ade0a258 --><ul><li><strong>Admit the person to hospital if they have severe nausea and vomiting </strong>and cannot tolerate oral fluids or symptomatic drug treatment.</li><li><strong>Refer the person to a balance specialist </strong>(audiovestibular physician or neurologist — depending on local protocol) for further assessment or consideration of vestibular rehabilitation, (involving exercises to promote central nervous system compensation) if:<ul><li>Symptoms are not typical of vestibular neuronitis (for example additional neurological symptoms).</li><li>Symptoms persist without improvement for more than 1 week despite treatment (urgently refer).</li><li>Symptoms persist for longer than 6 weeks — investigation to exclude other causes, or vestibular rehabilitation may be required.</li></ul></li></ul><!-- end field ca375e99-945b-426a-8fe6-8087ade0a258 --><!-- end item 1725e4d4-f04e-40b7-b9d0-ff0a56d38c24 -->","subChapters":[{"id":"ab4cfb2d-de5d-5b63-bcf0-44c539fdc128","slug":"basis-for-recommendation-7f0","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 251fdc98-35f9-424c-9793-9b1ac0b65e7c --><h4>Basis for recommendation</h4><!-- end field 251fdc98-35f9-424c-9793-9b1ac0b65e7c -->","summary":null,"htmlStringContent":"<!-- begin item 7f03b70c-8c9f-47ab-8e73-1c0365695191 --><!-- begin field 5f89c766-26a3-4cd7-a884-0ffc923e0f62 --><h5>Admission to hospital if severe nausea and vomiting are present</h5><ul><li>This recommendation is based on expert opinion in review articles that acknowledge that some people with vestibular neuronitis (especially those more susceptible to dehydration such as children, older people, and people with certain underlying medical conditions) will require intravenous hydration and medication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Goddard and Fayad, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Wipperman, 2014</a>].  </li></ul><h5>Referral to a balance specialist</h5><ul><li>Referral recommendations are based on expert opinion from:<ul><li>A review article on the diagnosis of vertigo in general practice [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Barraclough and Bronstein, 2009</a>].</li><li>A study reporting referral patterns for dizziness in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Bird et al, 1998</a>]. Referral criteria were formulated from expert opinion for this study.</li><li>Previous reviewers of this CKS topic, who suggest that it is appropriate to refer after 1 week to exclude more serious diagnoses if symptoms persist despite treatment.</li></ul></li></ul><h5>Consideration of vestibular rehabilitation</h5><ul><li>An evidence-based clinical practice guideline on vestibular rehabilitation for peripheral vestibular hypofunction (of which vestibular neuronitis is a common cause) recommends that clinicians offer vestibular rehabilitation to people with acute or subacute unilateral vestibular hypofunction based on good quality evidence showing improved outcomes in people undergoing vestibular rehabilitation compared with controls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">Hall et al, 2016</a>].  </li><li>There is evidence from a Cochrane systematic review (search date January 2014) that vestibular rehabilitation is effective and has a well-established safety profile for unilateral peripheral vestibular dysfunction, and that it helps symptoms and increases function in the medium term [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">McDonnell and Hillier, 2015</a>]. Expert opinion from previous reviewers of this CKS topic suggests that the quality and availability of vestibular rehabilitation varies depending on locality.</li></ul><!-- end field 5f89c766-26a3-4cd7-a884-0ffc923e0f62 --><!-- end item 7f03b70c-8c9f-47ab-8e73-1c0365695191 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}